# Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

> **NCT01081431** · PHASE2 · COMPLETED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 91 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01081431
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-26
- **Primary completion:** 2018-05-24
- **Final completion:** 2018-05-24
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081431, "Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01081431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*